Epidermal growth factor receptor-targeted agents for lung cancer

Cancer Control

Volumn 13, Issue 2, 2006, Pages 129-140

  Martin, Petra ^a   Kelly, Catherine M A ^a   Carney, Desmond ^a,b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b MATER PRIVATE HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; PACLITAXEL; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; GENE STRUCTURE; HEADACHE; HUMAN; LUNG CANCER; MUCOSA INFLAMMATION; MUTATION; NAUSEA; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RASH; REVIEW; SKIN TOXICITY; VOMITING;

EID: 33745186029     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300207     Document Type: Review

References (50)

1. Kelly K, Crowley J, Bunn Jr PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol. 2001;19:3210-3218.
2. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285-4291.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
4. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol. 2003;21:3016-3024. Epub 2003 Jul 1.
5. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000;18:131-135.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
7. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial E4599. Proc Annu Meet Am Soc Clin Oncol. 2005;24:LBA4. Abstract.
8. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556-2568. Epub 2005 Mar 14.
9. Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol. 1999;11:190-196.
10. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal. 2000;1:12-21.
11. Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001;71:1-20.
12. Salomon DS. Exon structure of the EGFR gene. Signal. 2004;5:30-31.
13. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell. 2002;109:275-282.
14. Baselga J. The science of EGFR inhibition: a roadmap to improved clinical outcomes? Signal. 2004;5:4-8.
15. Merlino GT, Ishii S, Whang-Peng J, et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol. 1985;5:1722-1734
16. Herbst RS. ZD 1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs. 2002;11:837-849.
17. Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitination and degradation of the ErbB receptor tyrosine kinases: implication for cancer therapy. EMBO J. 2002;21:2407-2417.
18. Astra Zeneca Oncology. IRESSA gefitinib monograph. AstraZeneca: Alderly House, Alderly Park, Macclesfield, Cheshire, UK; 7875/IREP0360/ August 2004.
19. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003;14:922-930.
20. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240-2250.
21. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor tyrosine kinase inhibitor ZD1839 is generally welltolerated and has activity in non-small-cell lung cancer and other solid tumors. Results of a phase I trial. J Clin Oncol. 2002;20:3815-3825.
22. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292-4302.
23. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237-2246. Epub 2003 May 14. Erratum in: J Clin Oncol. 2004;22:4811.
24. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA. 2003;290:2149-2158.
25. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003;39:55-61.
26. Lynch T, Ranson M, Herbst R, et al. Skin toxicity is not a clinically meaningful prognostic marker for tumor response to gefitinib (Iressa ZD1839) in pretreated patients with advanced non-small-cell lung cancer. Clin Cancer Res. 2003;9(suppl):6086s. A70 Abstract.
27. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (Iressa, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res. 2003;44:1362. Abstract LB-170.
28. Shah NT, Miller VA, Kris MG, et al. Bronchoalveolar histology and smoking history predict response to gefitinib (Iressa ZD1839). Proc Annu Meet Am Soc Clin Oncol. 2003;22:2524. Abstract.
29. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053-2063.
30. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885-4892.
31. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor underlying responsiveness to non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. Epub 2004 Apr 29.
32. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlations with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. Epub 2004 Apr 29.
33. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167. Epub 2004 Jul 29.
34. Arteaga C. Targeting HER 1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30(3 suppl 7):3-14.
35. Akita RW, Dugger D, Lewis Phillips G, et al. Effects of EGFR inhibitor Tarceva on activated ErbB2. Proc Am Soc Cancer Res. 2002;43:1003. Absract 4973.
36. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
37. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238-3247.
38. Gandara DR, Vokes E, Green M, et al. Activity of Docetaxel in platinum-treated non-small lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000;18:131-135.
39. Giaccone G, Lechevalier T, Thatcher N, et al. A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol. 2005;24:7073. Abstract.
40. Jackman D, Lucca J, Fidias P, et al. Phase II study of the EGFR tyrosine kinase erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. Proc Annu Meet Am Soc Clin Oncol. 2005;24:7148. Abstract.
41. Shepherd FA, Pereira J, Ciuleanu TE, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
42. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
43. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Jul 25; [Epub ahead of print].
44. Miller VA, Herbst R, Prager D, et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCI (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE. Proc Annu Meet Am Soc Clin Oncol. 2004;22(14S):7061. Abstract.
45. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and GC chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol. 2004;22(14S):7010. Abstract.
46. Nemunaitis JJ, Eiseman I, Cunningham C, et al. Phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2003;22:974. Abstract.
47. Shin DM, Nemunaitis J, Zinner RG, et al. A phase I clinical and biomarker study of CI-1033, a novel pan -erbB tyrosine kinase inhibitor in patients with solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2001;20:324. Abstract.
48. Adams VR, Bence AK, Anderson EB, et al. A phase I pharmacokinetic/ pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects. Proc Annu Meet Am Soc Clin Oncol. 2002;21:374. Abstract.
49. Burris HA, Taylor C, Jones S, et al. A phase 1 study of GW572016 in patients with solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2003;22:994. Abstract.
50. Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys. 2004;58:932-940.